Major Depressive Disorder (MDD)Depressive DisordersInterpersonal Functioning & Social ConnectednessPsilocybin

Psilocybin-Assisted Compassion Focused Therapy for Depression

This paper (2022) makes a case for using Compassion Focused Therapy (CFT) in tandem with psilocybin for the treatment of depression. The authors present a framework for using CFT as well as the rationale for selecting CFT, the compatibility of CFT and psilocybin-therapy, an overview of the psilocybin-assisted CFT protocol, the study protocol, and limitations to this approach.

Authors

  • Pots, W.
  • Chakhssi, F.

Published

Frontiers in Psychology
meta Study

Abstract

Psilocybin-assisted psychotherapy, i.e., psilocybin treatment with psychological support, has demonstrated the efficacy of psilocybin to reduce depressive symptoms. However, in clinical trials, the structure of psilocybin-assisted psychotherapy is primarily based on preparation, navigation (support during dosing sessions), and integration. For psychotherapeutic guidance, the application of this structure is favoured over the usage of theoretical models. The applied psychotherapeutic models may be of critical importance if the effects are augmented due to the psychologically insightful experiences during the navigation and integration sessions. One of the important next steps is to provide therapists with guidance on how to provide psilocybin-assisted psychotherapy. We present an integrated protocol for psilocybin-assisted psychotherapy for depression based on the theoretical model and psychotherapeutic framework of Compassion Focused Therapy (CFT). We hypothesize that CFT can provide the theoretical model and compassion practices that will reinforce the experiences during the navigation and follow-up therapy sessions. In this paper, we describe the rationale for selecting CFT, the compatibility of CFT and psilocybin-therapy, an overview of the psilocybin-assisted CFT protocol, the study protocol, and limitations to this approach.

Available with Blossom Pro

Research Summary of 'Psilocybin-Assisted Compassion Focused Therapy for Depression'

Introduction

Major depressive disorder remains highly prevalent and burdensome, and current psychotherapies and pharmacotherapies leave many patients without remission. Pots and colleagues note that psilocybin has emerged as a promising intervention for depression: it can alter glutamate signalling in key brain regions, produce changes in self-experience, and increase feelings of connectedness. Clinical trials using psilocybin with psychological support commonly adopt a preparatory–navigation–integration structure, but the psychotherapeutic content has often been non‑directive or minimally specified, and the contribution of an explicit psychotherapeutic model to clinical benefit is unclear. This paper sets out to embed psilocybin-assisted psychotherapy for depression within the theoretical and practical framework of Compassion Focused Therapy (CFT). The study aim is to present the rationale for selecting CFT, describe the compatibility of CFT with psilocybin-assisted therapy, and provide an operationalised treatment protocol and study design suggestions to examine its efficacy and feasibility. The authors propose that CFT practices may reinforce therapeutic processes during navigation (dosing) and integration, thereby enhancing clinical outcomes for depression.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (26)

Papers cited by this study that are also in Blossom

Emotions and brain function are altered up to one month after a single high dose of psilocybin

Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)

The therapeutic potential of psychedelic drugs: past, present, and future

Carhart-Harris, R. L., Goodwin, G. M. · Neuropsychopharmacology (2017)

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Carhart-Harris, R. L., Bolstridge, M., Rucker, J. et al. · Lancet Psychiatry (2016)

1174 cited
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

Davis, A. K., Barrett, F. S., May, D. G. et al. · JAMA Psychiatry (2021)

1015 cited
Ketamine administration in depressive disorders: a systematic review and meta-analysis

Fond, G., Loundou, A., Macgregor, A. et al. · Psychopharmacology (2014)

Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice

Palhano-Fontes, F., Gorman, I., Nielson, E. M. et al. · Frontiers in Psychology (2021)

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)

Show all 26 references
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

Griffiths, R. R., Richards, W. A., Mccann, U. et al. · Journal of Psychopharmacology (2006)

Role of the 5-HT2A receptor in acute effects of LSD on empathy and circulating oxytocin

Holze, F., Avedisian, I., Varghese, N. et al. · Frontiers in Pharmacology (2021)

Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy

Horton, D. M., Morrison, B., Schmidt, J. · American Journal of Psychotherapy (2021)

Long-term follow-up of psilocybin-facilitated smoking cessation

Johnson, M. W., Garcia-Romeu, A., Griffiths, R. R. · The American Journal of Drug and Alcohol Abuse (2016)

562 cited
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)

The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act

Johnson, M. W., Griffiths, R. R., Hendricks, P. S. et al. · Neuropharmacology (2018)

Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin

Mason, N. L., Kuypers, K. P. C., Reckweg, J. et al. · Neuropsychopharmacology (2020)

Psychedelics and the science of self-experience

Nour, M. R., Carhart-Harris, R. L. · British Journal of Psychiatry (2017)

Integrating Psychedelic Medicines and Psychiatry: Theory and Methods of a Model Clinic

Sloshower, J. A. · Plant Medicines Healing and Psychedelic Science (2018)

Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame

Sloshower, J., Guss, J., Krause, R. et al. · Journal of Contextual Behavioral Science (2020)

The use of the psychological flexibility model to support psychedelic assisted therapy

Watts, R., Luoma, J. B. · Journal of Contextual Behavioral Science (2020)

Patients’ accounts of increased “Connectedness” and “Acceptance” after psilocybin for treatment-resistant depression

Watts, R., Day, C. M., Krzanowski, J. et al. · Journal of Humanistic Psychology (2017)

Cited By (2)

Papers in Blossom that reference this study

Classic Psychedelic Use and Current Meditation Practice

Simonsson, A., Simonsson, O., Chambers, R. et al. · Mindfulness (2023)

14 cited

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.

Psilocybin-Assisted Compassion Focused Therapy... — Research Summary & Context | Blossom